- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Inhibitors
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 89786-04-9] Tazobactam
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-B1418 |
| Brand: | MCE |
| CAS: | 89786-04-9 |
Overview
| MDL | MFCD00867002 |
|---|---|
| Molecular Weight | 300.29 |
| Molecular Formula | C10H12N4O5S |
| SMILES | O=C([C@@H]([C@@](CN1N=NC=C1)(C)S([C@]2([H])C3)(=O)=O)N2C3=O)O |
4 Publications Citing Use of MCE
Summary
Tazobactam (CL-298741) is a potent β-lactamases inhibitor and penicillin antibiotic . Tazobactam has antibacterial activity. Tazobactam can be used for pneumonia research [1] [2] .
In Vitro
Tazobactam (CL-298741) (5 μg/mL; 18 hours) has bactericidal activity and inhibit the growth of the bacteria in a dose-dependent manner
[2]
.
Tazobactam (CL-298741) (1-10 μg/mL; 6 hours;
Prot. vulgaris
and
M. morgan
) inhibits various types β-lactamase activity and with ID
50
values of ＜ 10 μg/mL, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Tazobactam (CL-298741) (1000 mg/kg; i.p.; four times a day, for 36 and 84 hours; BALB/c mice) decreases the number of bacteria in mice and survived in low doses [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | BALB/c mice [1] |
| Dosage: | 1000 mg/kg |
| Administration: | Intraperitoneal injection; four times a day, for 36 and 84 hours |
| Result: | Decraesed the number of bacteria and neutrophils in BALF than in the control group. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT04948463 | Murdoch Childrens Research Institute |
Febrile Neutropenia
|
November 15, 2021 | Phase 4 |
| NCT00003805 | European Organisation for Research and Treatment of Cancer - EORTC |
Bone Marrow Suppression|Fever, Sweats, and Hot Flashes|Infection|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Unspecified Adult Solid Tumor, Protocol Specific|Unspecified Childhood Solid Tumor, Protocol Specific
|
November 1997 | Phase 3 |
| NCT00389987 | Merck Sharp & Dohme LLC |
Complicated Intra-Abdominal Infections
|
September 2001 | Phase 3 |
| NCT03289351 | Phoenix Children´s Hospital |
Perforated Appendicitis|Postoperative Infection
|
May 22, 2017 | Phase 4 |
| NCT03765645 | Institute of Liver and Biliary Sciences, India |
Antibiotic Prophylaxis|Postoperative Infection
|
October 4, 2018 | Not Applicable |
| NCT02817347 | Yuhan Corporation |
Otitis Media|Otorrhea
|
June 2016 | Phase 1|Phase 2 |
| NCT05608564 | University of Belgrade |
Periodontitis
|
January 17, 2022 | Not Applicable |
| NCT05355350 | Rambam Health Care Campus|The Chaim Sheba Medical Center|Rabin Medical Center|Hadassah Medical Organization |
Beta Lactam Resistant Bacterial Infection|Enterobacteriaceae Infections|Bacteremia
|
July 1, 2022 | Phase 4 |
| NCT02709382 | Wockhardt|Clinartis |
Renal Impairment
|
March 2016 | Phase 1 |
| NCT03891433 | Universidad del Norte |
Urinary Tract Infections|Enterobacteriaceae Infections|Infection Due to ESBL Bacteria|Carbapenem|Escherichia Coli Infection|Klebsiella Pneumoniae Infection|Clinical Trial|Drug Resistance, Bacterial
|
April 1, 2019 | Phase 4 |
| NCT03485950 | M.D. Anderson Cancer Center|Merck Sharp & Dohme LLC|National Cancer Institute (NCI) |
Other Infectious Diseases
|
May 16, 2018 | Phase 2 |
| NCT04673175 | Weill Medical College of Cornell University|Merck Sharp & Dohme LLC |
Pseudomonas Aeruginosa|Pneumonia|Hematologic Malignancy
|
July 20, 2022 | Phase 1|Phase 2 |
| NCT01994993 | Michael Cohen-Wolkowiez|The Emmes Company, LLC|Duke University |
Complicated Intra Abdominal Infections
|
December 2013 | Phase 2|Phase 3 |
| NCT03990467 | Hospices Civils de Lyon |
Septic Shock|Sepsis|Sepsis Syndrome
|
January 28, 2021 | Not Applicable |
| NCT01667094 | The Alfred |
Cystic Fibrosis
|
September 2012 | Phase 4 |
| NCT01147640 | Cubist Pharmaceuticals LLC |
Complicated Intra-abdominal Infection
|
June 25, 2010 | Phase 2 |
| NCT02493764 | Merck Sharp & Dohme LLC |
Bacterial Pneumonia
|
November 24, 2015 | Phase 3 |
| NCT02473263 | Assistance Publique - Hôpitaux de Paris |
Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit
|
May 9, 2016 | Phase 3 |
Appearance
Solid
Source
Gram-negative bacilli
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 166.51 mM ; Need ultrasonic)
H 2 O : 1 mg/mL ( 3.33 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.3301 mL | 16.6506 mL | 33.3011 mL |
| 5 mM | 0.6660 mL | 3.3301 mL | 6.6602 mL |
| 10 mM | 0.3330 mL | 1.6651 mL | 3.3301 mL |
References
- [1] Harada Y, et, al. In vitro and in vivo activities of piperacillin-tazobactam and meropenem at different inoculum sizes of ESBL-producing Klebsiella pneumoniae. Clin Microbiol Infect. 2014 Nov;20(11):O831-9.
- [2] Higashitani F, et, al. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. J Antimicrob Chemother. 1990 Apr;25(4):567-74.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.